Scholarlink

Background <p>Thromboembolism (TE) is a serious complication in lymphoma, driving excess morbidity and mortality. Existing prediction tools perform suboptimally in lymphoma-specific settings.</p> Methods <p>We retrospectively analysed 790 newly diagnosed lymphoma patients (January 2019–December 2021). Patients were randomly split 7:3 into development and internal-validation cohorts. Forty-eight candidate predictors were screened with LASSO, followed by multivariable Cox modelling to construct a nomogram. Discrimination and calibration were assessed at 6, 12 and 24 months using time-dependent ROC analysis and bootstrap calibration.</p> Results <p>TE occurred in 77/790 patients (9.8%). Independent predictors were ECOG performance status, prior venous thromboembolism (VTE), coronary artery disease, central venous catheterisation, and APTT category. The nomogram showed good discrimination: AUCs were 0.813, 0.818 and 0.733 at 0.5, 1.0 and 2.0 years in the development cohort, and 0.724, 0.731 and 0.659 in the validation cohort. Conventional scores performed poorly in this population (e.g., at 1 year ThroLy 0.587 vs. Khorana 0.527). Calibration plots indicated close agreement between predicted and observed risks. Patients who experienced TE had poorer overall survival, with the greatest divergence in survival curves occurring within the first six months after diagnosis.</p> Conclusions <p>This lymphoma-specific model improves TE risk stratification and can inform individualised prophylaxis and early monitoring. External, multi-centre validation is warranted to confirm generalisability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and internal validation of a lymphoma-specific nomogram for predicting venous thromboembolism: a retrospective cohort of 790 patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月5日

查看全文
  • Lili Pan,
  • Wenzheng Lin,
  • Yanyan Qiu,
  • Jinhua Chen,
  • Nainong Li,
  • Tingbo Liu

摘要

Background

Thromboembolism (TE) is a serious complication in lymphoma, driving excess morbidity and mortality. Existing prediction tools perform suboptimally in lymphoma-specific settings.

Methods

We retrospectively analysed 790 newly diagnosed lymphoma patients (January 2019–December 2021). Patients were randomly split 7:3 into development and internal-validation cohorts. Forty-eight candidate predictors were screened with LASSO, followed by multivariable Cox modelling to construct a nomogram. Discrimination and calibration were assessed at 6, 12 and 24 months using time-dependent ROC analysis and bootstrap calibration.

Results

TE occurred in 77/790 patients (9.8%). Independent predictors were ECOG performance status, prior venous thromboembolism (VTE), coronary artery disease, central venous catheterisation, and APTT category. The nomogram showed good discrimination: AUCs were 0.813, 0.818 and 0.733 at 0.5, 1.0 and 2.0 years in the development cohort, and 0.724, 0.731 and 0.659 in the validation cohort. Conventional scores performed poorly in this population (e.g., at 1 year ThroLy 0.587 vs. Khorana 0.527). Calibration plots indicated close agreement between predicted and observed risks. Patients who experienced TE had poorer overall survival, with the greatest divergence in survival curves occurring within the first six months after diagnosis.

Conclusions

This lymphoma-specific model improves TE risk stratification and can inform individualised prophylaxis and early monitoring. External, multi-centre validation is warranted to confirm generalisability.